Cytokinetics, (CYTK)
|
1.03
-0.07 (-6.36%)
|
|
|
|
CYTK additional information
Market Data powered by QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Filings and Fundamentals by Morningstar, Insiders by Vickers (USA) and SEDI(CDN), analyst ratings by Zacks.
CYTK Profile
•
Exchange
NASDAQ
•
Held by these Mutual Funds
Hartford Global Health A
Hartford SmallCap Growth HLS IA
Prudential Jennison Blend B
General American Investors
iShares Nasdaq Biotechnology
Hartford Global Health HLS IA
Vanguard Extended Market Idx
iShares Russell 2000 Growth Index
DFA US Micro Cap I
CREF Stock
Hartford SmallCap Growth HLS IA
Prudential Jennison Blend B
General American Investors
iShares Nasdaq Biotechnology
Hartford Global Health HLS IA
Vanguard Extended Market Idx
iShares Russell 2000 Growth Index
DFA US Micro Cap I
CREF Stock
•
Executives
Mr. Robert I. Blum
Chief Exec. Officer
Pres Director and Chief Exec. of the Biopharmaceutical Concern
Ms. Sharon Surrey-Barbari
Chief Financial Officer
Principal Accounting Officer Exec. VP of Fin. and Sec.
Dr. Andrew A. Wolff M.D. A.C.C.
57
Chief Medical Officer and Sr. VP of Clinical R&D
Mr. David W. Cragg
Sr. VP of HR
Dr. James Sabry M.D. .D.
53
Co-Founder Chairman of Scientific Advisory Board and Consultant
Chief Exec. Officer
Pres Director and Chief Exec. of the Biopharmaceutical Concern
Ms. Sharon Surrey-Barbari
Chief Financial Officer
Principal Accounting Officer Exec. VP of Fin. and Sec.
Dr. Andrew A. Wolff M.D. A.C.C.
57
Chief Medical Officer and Sr. VP of Clinical R&D
Mr. David W. Cragg
Sr. VP of HR
Dr. James Sabry M.D. .D.
53
Co-Founder Chairman of Scientific Advisory Board and Consultant
•
Employee Count
83
Special Offers
Competitors
CYTK earnings
Date
Actual
Expected
Prev Yr Qtr
10/30/2012
-0.15
-0.11
-0.15
7/31/2012
-0.13
-0.13
-0.23
4/26/2012
-0.13
-0.14
-0.18
